Caribou Biosciences, Inc. (CRBU)
Healthcare · NMS
Price as at 30 Sept 2026, 17:17 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Caribou Biosciences, Inc. trades at $1.27, which is 17% above the $1.05 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 11 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CRBU earnings and analyst estimates
Recommendation mix, 7 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
CRBU passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$4.88M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.84M · 0.0% of book
- Lee Ainslie, MAVERICK CAPITAL LTD$1.15M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$661.2K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$90.1K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
CRBU peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Caribou Biosciences, Inc. (CRBU) undervalued?
Against our fair value estimate of $1.05, CRBU at $1.27 is 17% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own CRBU?
7 of the institutions we track reported a position in CRBU in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its CRBU data?
Fundamentals for CRBU come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:17 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CRBU, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.